JoVE - Journal of Visualized Experiments
JoVE Visualize
Contact Us

Translational analysis of NSD3 gene amplification in lung squamous cell carcinoma: Clinical and prognostic insights from histopathological analysis of patient samples

  • 0Department of Pathology and Clinical Laboratories, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Department of Thoracic Surgery, National Cancer Center Hospital East, Kashiwa, Chiba, Japan; Course of Advanced Clinical Research of Cancer, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer +

|

September 5, 2025

|

September 5, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Nuclear receptor-binding SET domain 3 (NSD3) amplification is common in lung squamous cell carcinoma (LUSC) and linked to poorer survival. This study confirms NSD3 amplification as a prognostic biomarker and potential therapeutic target in LUSC patients.

Area Of Science

  • Oncology
  • Molecular Biology
  • Genetics

Background

  • Nuclear receptor-binding SET domain 3 (NSD3) is a potential driver in lung squamous cell carcinoma (LUSC).
  • The clinical significance and prognostic role of NSD3 in LUSC are not well-established.
  • Preclinical data suggest NSD3's involvement in LUSC pathogenesis.

Purpose Of The Study

  • To investigate the clinicopathological characteristics of NSD3 amplification in LUSC.
  • To determine the prognostic significance of NSD3 amplification in LUSC patients.
  • To explore the association between NSD3 amplification, protein expression, and tumor proliferation.

Main Methods

  • Histopathological analysis of surgically resected LUSC tissues from multiple cohorts.
  • Fluorescence in situ hybridization (FISH) to assess NSD3 gene copy number (amplification vs. diploidy).
  • AI-based image analysis to correlate NSD3 amplification with protein expression and Ki-67 proliferation index.

Main Results

  • NSD3 amplification detected in 39.6% of LUSC cases.
  • NSD3 amplification correlated with increased NSD3 protein expression and higher Ki-67 index.
  • Patients with NSD3 amplification showed significantly shorter overall survival and it was an independent poor prognostic factor.

Conclusions

  • NSD3 amplification is clinically relevant in LUSC and associated with aggressive tumor behavior.
  • NSD3 amplification serves as a potential prognostic biomarker for LUSC.
  • Targeting NSD3 may offer a novel therapeutic strategy for LUSC, translating preclinical findings to clinical practice.

Keywords: